Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CCTG is delighted to announce that Dr. Alexander Wyatt has become the new Correlative Sciences Committee Chair for the CCTG GU disease site committee.
Dr. Wyatt is an Assistant Professor in Urologic Sciences at the University of British Columbia, a Senior Research Scientist at the Vancouver Prostate Centre, and Scientist at the BC Cancer Genome Sciences Centre. He has a PhD in genetics (University of Oxford), and now specializes in human genitourinary cancer genomics and bio informatics
Meet Martina Wood a breast cancer survivor and a member of the CCTG breast committee. Our teams are proud to work with volunteers like Martina who ensure the patient voice is part of our clinical trial development.
The Canadian Cancer Trials Group (CCTG), at Queen’s University, asks and finds evidence-based answers to critical questions about the best treatment options for the 225,000 Canadians diagnosed with cancer each year. Innovations proven to be effective through CCTG led clinical trials have set new standards of care that guide treatment decisions for patients today and tomorrow: curing disease, preventing recurrence, saving lives, and improving quality of life. See full article here.
A paper has recently been published in Current Oncology outlining the incorporation of patient engagement in the development of clinical trial at the Canadian Cancer Trials Group (CCTG).
A recent abstract presented at GI ASCO 2021: Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
The UK National Cancer Research Institute (NCRI) has cited the CCTG PR13 study (RADICALS-RT) as one of their top three achievements of the year in their 2019-2020 annual report! https://www.ncri.org.uk/wp-content/uploads/NCRI-Prostate-Group-Annual-Report-2019-20.pdf
CCTG SR7: A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS-2), has been centrally activated.
For our Canadian member sites a COVID-19 reminder to keep the CCTG updated on trial activities at your site.
